Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is
China Securities Co.,Ltd: Accelerating development of the self-immunity market to promote the improvement and efficiency of the domestic innovative drug industry.
The patient population with autoimmune diseases and type II inflammation is growing rapidly, the market size is second only to cancer drugs, but still in a period of accelerated development. Existing drugs still have huge room for improvement in efficacy and safety.
Hong Kong stocks anomaly | Zai Lab (09688) rose more than 3% again. Recently, it announced that its Egamod subcutaneous injection was approved domestically in collaboration with Argenx.
Zai Lab (09688) rose more than 3% again. As of press time, it rose 3.50% to HKD 14.78, with a turnover of HKD 9.3122 million.
Express News | Argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection for Generalized Myasthenia Gravis in China
Asian Equities Traded in the US as American Depositary Receipts Move Modestly Higher in Tuesday Trading
Asian equities traded in the US as American depositary receipts were trending modestly higher Tuesday morning, rising 0.30% to 2,037.69 on the S&P Asia 50 ADR Index.From North Asia, the gainers were
HKEX News | Zai Lab (09688) rose over 4% in the afternoon, as Edaravone Injection was approved domestically for the treatment of generalized myasthenia gravis.
Zai Lab (09688) rose more than 4% in the afternoon and at the time of publication, it rose 3.64%, at HKD 14.24, with a turnover of HKD 29.885 million.
Express News | Zai Lab And Argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China
Express News | Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Zai Lab-Supported Study Published in Cell Provides New Insights With Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
Manuscript represents the first publication from China's gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified
Zai Lab Is Maintained at Overweight by JP Morgan
Zai Lab Is Maintained at Overweight by JP
JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating
Zai Lab (ZLAB) has an average rating of buy and price targets ranging from $21 to $66, according to analysts by Capital IQ.Price: 18.37, Change: +0.52, Percent Change: +2.94
Express News | JP Morgan Maintains Overweight on Zai Lab, Lowers Price Target to $38
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading
Asian equities traded in the US as American depositary receipts were moving sharply higher Friday morning, rising 1.2% to 2,061.9 on the S&P Asia 50 ADR Index. With the gain, the index is poised to
J.P. Morgan Maintains Zai Lab(ZLAB.US) With Buy Rating, Cuts Target Price to $38
J.P. Morgan analyst Anupam Rama maintains $Zai Lab(ZLAB.US)$ with a buy rating, and adjusts the target price from $43 to $38.According to TipRanks data, the analyst has a success rate of 47.0% and a
Express News | JPMorgan Chase & Co's Long Position in Zai Lab Increases to 13.11% on July 9 From 12.46% - HKEX
Express News | Zai Lab Ltd : JP Morgan Cuts Target Price to $38 From $43
Hong Kong stocks rebounded again, with pharmaceutical stocks rising, and the industry's investment and financing are expected to hit bottom and rebound. The release of innovative drug policies has provided bullish signals.
According to the Zhongtong Finance APP, pharmaceutical stocks have risen again. As of press time, Kexing Biotech-B (06990) rose 9.07%, reporting HKD 155.1; Zai Lab (09688) rose 4.63%, reporting HKD 14.02; Genscript Biotech (01548) rose 4.59%, reporting HKD 10.02; and Innocare (09969) rose 4.57%, reporting HKD 5.03. On the news front, the US June CPI slowed down more than expected, pushing the probability of a rate cut in September to nearly 90%. Pacific Securities pointed out that as the Fed's rate hike cycle comes to an end in the future, liquidity is expected to gradually ease.
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
Company to Host Conference Call and Webcast on August 7, 2024, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report financial results for the second quarter
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Cuts Target Price to $21
BofA Securities analyst David Li maintains $Zai Lab(ZLAB.US)$ with a buy rating, and adjusts the target price from $25 to $21.According to TipRanks data, the analyst has a success rate of 16.2% and
Reaffirming Buy on Zai Lab Amid Strong Sales and Solid R&D Despite Rising Competition